Product Description
OCV-C02 is a peptide vaccine consisting of two peptide epitopes derived from ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34 (TOMM34). a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28266765/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| JapicCTI-132075 | P1 |
Unknown |
Colorectal Cancer |
2015-01-01 |
|||
| JapicCTI-132075 | P1 |
Completed |
Colorectal Cancer |
2015-01-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|